These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 27610264)

  • 1. Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application.
    Xu L; Pu J
    Parkinsons Dis; 2016; 2016():1720621. PubMed ID: 27610264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease.
    Pavlou MAS; Pinho R; Paiva I; Outeiro TF
    Brain; 2017 Apr; 140(4):878-886. PubMed ID: 27585855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of
    Magistrelli L; Contaldi E; Comi C
    Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-synuclein-based models of Parkinson's disease.
    Dehay B; Fernagut PO
    Rev Neurol (Paris); 2016; 172(6-7):371-8. PubMed ID: 27158042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.
    Dehay B; Bourdenx M; Gorry P; Przedborski S; Vila M; Hunot S; Singleton A; Olanow CW; Merchant KM; Bezard E; Petsko GA; Meissner WG
    Lancet Neurol; 2015 Aug; 14(8):855-866. PubMed ID: 26050140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More than a Rumor Spreads in Parkinson's Disease.
    Prymaczok NC; Riek R; Gerez J
    Front Hum Neurosci; 2016; 10():608. PubMed ID: 27994545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-(1-7) reduces α-synuclein aggregation by enhancing autophagic activity in Parkinson's disease.
    Gao Q; Chen R; Wu L; Huang Q; Wang XX; Tian YY; Zhang YD
    Neural Regen Res; 2022 May; 17(5):1138-1145. PubMed ID: 34558543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A crazy trio in Parkinson's disease: metabolism alteration, α-synuclein aggregation, and oxidative stress.
    Li S; Liu Y; Lu S; Xu J; Liu X; Yang D; Yang Y; Hou L; Li N
    Mol Cell Biochem; 2024 Apr; ():. PubMed ID: 38625515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-synuclein pathogenesis in hiPSC models of Parkinson's disease.
    Baena-Montes JM; Avazzadeh S; Quinlan LR
    Neuronal Signal; 2021 Jun; 5(2):NS20210021. PubMed ID: 34239711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One ring is sufficient to inhibit α-synuclein aggregation.
    Pena-DIaz S; Ventura S
    Neural Regen Res; 2022 Mar; 17(3):508-511. PubMed ID: 34380879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J; Uversky VN; Fink AL
    Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein and Parkinsonism: Updates and Future Perspectives.
    Rosborough K; Patel N; Kalia LV
    Curr Neurol Neurosci Rep; 2017 Apr; 17(4):31. PubMed ID: 28324300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?
    O'Hara DM; Pawar G; Kalia SK; Kalia LV
    Front Neurosci; 2020; 14():577. PubMed ID: 32625052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.